Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3+ regulatory T cells

被引:254
作者
Ladoire, Sylvain [1 ,2 ]
Arnould, Laurent [2 ]
Apetoh, Lionel [3 ]
Coudert, Bruno [2 ]
Martin, Francois [1 ]
Chauffert, Bruno [1 ,2 ]
Fumoleau, Pierre [2 ]
Ghiringhelli, Francois [1 ,2 ,3 ]
机构
[1] INSERM, Ctr Rech 866, Ctr Georges Francois Leclerc, Fac Med, F-21000 Dijon, France
[2] INSERM, Ctr Rech 866, Ctr Reg Lutte Contre Canc, F-21000 Dijon, France
[3] Inst Gustave Roussy, Villejuif, France
关键词
D O I
10.1158/1078-0432.CCR-07-4491
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: T-cell infiltration is associated with good tumor prognosis in many cancers. To assess the capacity of neoadjuvant chemotherapy to affect T-cell infiltration in breast cancer, we evaluated CD3 and CD8 infiltrates, and the Foxp3 immunosuppressive T cells. Experimental Design: CD3(+), CD8(+), and Foxp3(+) cell infiltrates were detected by immunohistochemistry in a series of 56 breast cancer patients before and after the end of neoadjuvant chemotherapy. Results: Poor prognostic factors (negative hormonal receptors, high tumor grade, and nodal involvement) were associated with a significantly higher number of CD3, CD8, and Foxp3 infiltrates before the beginning of chemotherapy, Chemotherapy resulted in a decrease in Foxp3 infiltrates, whereas the level of CD8 and CD3 infiltrates remained unchanged. Pathologic complete responses (pCR) had a drastic decrease of Foxp3(+) cells, whereas these cells remained elevated in nonresponders. A cutoff criterion that combined high CD8 infiltration and no Foxp3 cell infiltration on surgical specimens is associated with pCR with a sensitivity of 75% and a specificity of 93%. The infiltrate of cytotoxic TiA1 and granzyme B - positive cells was dramatically enhanced after chemotherapy only in patients with pCR. By multivariate analysis, association of a high CD8 infiltration and no Foxp3 infiltration on final histologic specimens were independently associated with pCR. Conclusion: These findings indicate that pCR to neoadjuvant chemotherapy is associated with an immunologic profile combining the absence of immunosuppressive Foxp3 cells and the presence of a high number of CD8 T cells and cytotoxic cells. These results argue for the induction of an antitumor immune response by chemotherapy.
引用
收藏
页码:2413 / 2420
页数:8
相关论文
共 32 条
[11]   Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients [J].
Ghiringhelli, Francois ;
Menard, Cedric ;
Puig, Pierre Emmanuel ;
Ladoire, Sylvain ;
Roux, Stephan ;
Martin, Francois ;
Solary, Eric ;
Le Cesne, Axel ;
Zitvogel, Laurence ;
Chauffert, Bruno .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (05) :641-648
[12]  
Ichihara F, 2003, CLIN CANCER RES, V9, P4404
[13]   Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy [J].
Kuerer, HM ;
Newman, LA ;
Smith, TL ;
Ames, FC ;
Hunt, KK ;
Dhingra, K ;
Theriault, RL ;
Singh, G ;
Binkley, SM ;
Sneige, N ;
Buchholz, TA ;
Ross, MI ;
McNeese, MD ;
Buzdar, AU ;
Hortobagyi, GN ;
Singletary, SE .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :460-469
[14]   T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma [J].
Ladányi, A ;
Somlai, B ;
Gilde, K ;
Fejös, Z ;
Gaudi, I ;
Tímár, J .
CLINICAL CANCER RESEARCH, 2004, 10 (02) :521-530
[15]   A better way for a cancer cell to die [J].
Lake, RA ;
van der Most, RG .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (23) :2503-2504
[16]   Opinion - Immunotherapy and chemotherapy - a practical partnership [J].
Lake, RA ;
Robinson, BWS .
NATURE REVIEWS CANCER, 2005, 5 (05) :397-405
[17]   Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma [J].
Liyanage, UK ;
Moore, TT ;
Joo, HG ;
Tanaka, Y ;
Herrmann, V ;
Doherty, G ;
Drebin, JA ;
Strasberg, SM ;
Eberlein, TJ ;
Goedegebuure, PS ;
Linehan, DC .
JOURNAL OF IMMUNOLOGY, 2002, 169 (05) :2756-2761
[18]  
Machiels JPH, 2001, CANCER RES, V61, P3689
[19]  
Naito Y, 1998, CANCER RES, V58, P3491
[20]  
Nakano O, 2001, CANCER RES, V61, P5132